The effects of the acute administration of TRPA1 agonists on safety, efficacy, and the biomechanical events of swallowing were investigated in a three-arm, quadruple-blind, randomized clinical trial that included patients with oropharyngeal dysphagia associated with aging, stroke, or neurodegenerative diseases [82]. The gene discussed is TRPA1; the disease is stroke disorder.